卡博替尼联合伊匹木单抗/纳武利尤单抗治疗经治晚期分化型甲状腺癌
这项研究者发起的II期试验评估卡博替尼联合纳武利尤单抗和伊匹木单抗(CaboNivoIpi)在经治放射性碘难治性分化型甲状腺癌中的疗效。11例入组,10例可评估,前6个月内客观缓解率为10%(1例部分缓解),未达到预设疗效阈值。中位无进展生存期9个月,中位总生存期19.2个月,3/4级治疗相关不良事件发生率为55%(6/11),5级为18%(2/11)。
要点
- CaboNivoIpi在经治放射性碘难治性分化型甲状腺癌中客观缓解率低(10%,1/10例部分缓解)。
- 中位无进展生存期9个月(95%CI 3.0-未达到),中位总生存期19.2个月(95%CI 4.6-未达到)。
- 3/4级治疗相关不良事件发生率55%(6/11),5级不良事件18%(2/11),研究未达到预设疗效阈值。
核心结论
- CaboNivoIpi的客观缓解率低,且≥3级治疗相关不良事件发生率高。
- 研究未达到预设的疗效阈值。
研究设计与样本
- 研究者发起的II期试验,纳入经1线血管内皮生长因子受体靶向治疗后进展的放射性碘难治性分化型甲状腺癌患者。
- 患者先接受2周卡博替尼单药导入,随后接受CaboNivoIpi治疗4个周期(周期长度6周),之后接受卡博替尼联合纳武利尤单抗(周期长度4周)直至疾病进展。
- 主要终点为治疗前6个月内的客观缓解率;采用Simon最优两阶段设计,10例可评估患者后进行中期分析,至少需5例缓解才能进入第二阶段。
- 共入组11例患者,中位年龄69岁;既往血管内皮生长因子受体靶向治疗包括仑伐替尼、帕唑帕尼和索拉非尼联合依维莫司。
- 中位随访时间为7.9个月。
主要发现
- 10例可评估患者中,治疗前6个月内客观缓解率为10%(1例部分缓解)。
- 中位无进展生存期为9个月(95%CI,3.0-未达到),中位总生存期为19.2个月(95%CI,4.6-未达到)。
- 3/4级治疗相关不良事件发生率为55%(6/11),5级治疗相关不良事件发生率为18%(2/11)。
- 最常见的治疗相关不良事件为高血压。
关键数值与推荐
- 主要终点客观缓解率在10例可评估患者中为10%(1例部分缓解)。
- 中期分析要求至少5例缓解才能进入第二阶段,研究未达到预设疗效阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This investigator-initiated phase II trial aimed to evaluate the efficacy of cabozantinib in combination with nivolumab and ipilimumab (CaboNivoIpi) in previously treated patients with radioactive iodine-refractory differentiated thyroid cancer. METHODS: Eligible patients with radioactive iodine-refractory differentiated thyroid cancer who progressed on 1 prior line of vascular endothelial growth factor receptor-targeted therapy received a 2-week run-in of cabozantinib monotherapy followed by CaboNivoIpi for 4 cycles (cycle length = 6 weeks), followed by cabozantinib plus nivolumab (cycle length = 4 weeks) until disease progression. The primary endpoint was objective response rate (ORR) within the first 6 months of treatment. A Simon optimal 2-stage design allowed for an interim analysis after accrual of 10 evaluable patients. At least 5 responses were needed to proceed to stage 2. RESULTS: Among 11 patients enrolled, the median age was 69 years. Prior vascular endothelial growth factor receptor-targeted therapies included lenvatinib, pazopanib, and sorafenib plus everolimus. Median follow-up was 7.9 months. Among 10 evaluable patients, ORR within the first 6 months of treatment was 10% (1 partial response). Median progression-free survival was 9 months (95% CI, 3.0-not reached) and median overall survival was 19.2 months (95% CI, 4.6-not reached). Grade 3/4 treatment-related adverse events (AEs) were noted in 55% (6/11) and grade 5 AEs in 18% (2/11) of patients. The most common treatment-related AE was hypertension. The study did not reach its prespecified efficacy threshold. CONCLUSION: CaboNivoIpi had low ORRs and a high rate of grade ≥3 treatment-related AEs. CLINICAL TRIAL REGISTRATION: NCT03914300.
引用
- Konda B, Sherman EJ, Massarelli E, et al. Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer. J Clin Endocrinol Metab. 2025. PMID: 39133806. doi:10.1210/clinem/dgae512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。